A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...
Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...
This peer-reviewed publication marks an important milestone following initial release of study information in August 2024 (see "Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT"). The ...
An aggressive breast cancer lacking common drug targets, triple-negative breast cancer may be countered by oridonin, a ...
A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has ...
A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for ...
Circadian rhythms are endogenous oscillations widely present in living organisms, typically following approximately 24-hour ...
In a proof-of-concept, placebo-controlled trial, the investigational oral selective AKT inhibitor engasertib appeared to be ...
Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting one in ...
For more details about SABCS please visit: https://www.sabcs.org/.
Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback